1. Academic Validation
  2. Prkci promotes colorectal cancer metastasis by phosphorylating and stabilizing Tgfbr1 to activate TGF-β signaling

Prkci promotes colorectal cancer metastasis by phosphorylating and stabilizing Tgfbr1 to activate TGF-β signaling

  • Cell Commun Signal. 2025 May 17;23(1):230. doi: 10.1186/s12964-025-02236-6.
Peng Li 1 Guangshi Liu 2 Wenbin Zhang 3 Tao Li 2
Affiliations

Affiliations

  • 1 Gastrointestinal Surgery department, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, Urumqi, 830000, China. lp20014@163.com.
  • 2 Gastrointestinal Surgery department, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, Urumqi, 830000, China.
  • 3 Department of Gastrointestinal Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, 830001, China.
Abstract

Colorectal Cancer is one of the most common malignancies worldwide, with metastasis being the leading cause of cancer-related mortality. However, the molecular mechanisms driving CRC metastasis remain poorly understood. In this study, we identified Prkci as a critical oncogenic driver in CRC metastasis. Prkci was significantly upregulated in metastatic CRC tissues. Mechanistically, Prkci phosphorylated and stabilized Tgfbr1, a key receptor in the Transforming Growth Factor Beta signaling pathway, preventing its proteasomal degradation and amplifying downstream signaling cascades. This stabilization promoted epithelial-to-mesenchymal transition, enhancing migratory and invasive capacities of CRC cells. In vivo, Prkci knockout significantly reduced liver and lung metastases and prolonged survival in mouse models, highlighting its therapeutic potential. These findings establish Prkci as a promising therapeutic target for suppressing CRC metastasis and improving outcomes for metastatic CRC patients.

Keywords

Colorectal cancer; Metastasis; Prkci; TGF-β signaling; Tgfbr1.

Figures
Products
Inhibitors & Agonists
Other Products